• Explore /
  • Poster
  • / Phase 1/2a study of AZD5305, a novel poly(adenosine diphosphate ribose) polymerase (PARP) 1-selective inhibitor in combination with new hormonal agents (NHAs) in patients (pts) with metastatic prostate cancer (mPC).

Phase 1/2a study of AZD5305, a novel poly(adenosine diphosphate ribose) polymerase (PARP) 1-selective inhibitor in combination with new hormonal agents (NHAs) in patients (pts) with metastatic prostate cancer (mPC).

Abstract Poster

Authors

null

Arun Azad

Peter MacCallum Cancer Centre, Melbourne, Australia

Arun Azad , Mark Voskoboynik , Ana Filipa Palma dos Reis , Anthony M. Joshua , Andrew James Weickhardt , Robert J. Jones , Pasquale Rescigno , Ben Tran , Caroline Kennedy , Spiros Linardopoulos , Ganesh Moorthy , TJ Zhou , Jessica S Brown , Edit Lukacs , Richard Francis , Andrew Hudson

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Genitourinary Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session A: Prostate Cancer

Track

Prostate Cancer - Advanced,Prostate Cancer - Localized

Sub Track

Other

Clinical Trial Registration Number

NCT05367440

Citation

J Clin Oncol 41, 2023 (suppl 6; abstr TPS296)

DOI

10.1200/JCO.2023.41.6_suppl.TPS296

Abstract #

TPS296

Poster Bd #

Q18

Abstract Disclosures

Similar Posters

First Author: Arun Azad

First Author: Arpit Rao

Poster

2023 ASCO Quality Care Symposium

Perceptions of emerging PARP inhibitor (PARPi) data among practicing oncologists in prostate cancer.

Perceptions of emerging PARP inhibitor (PARPi) data among practicing oncologists in prostate cancer.

First Author: Nicholas Moffett

First Author: Arpit Rao